Skip to main content
. 2016 Apr 18;7(22):32969–32979. doi: 10.18632/oncotarget.8808

Figure 5. SH003 inhibits VEGF binding to VEGFR2.

Figure 5

A-B. SH003 and btVEGF were treated on the plate where recombinant human VEGFR2 or VEGFR1 was coated. C-F. Cucurbitacin D, decursin, formononetin, or nodakenin together with btVEGF were treated on the plate where recombinant human VEGFR2 was coated.